September 10, 2025Annals of HematologyOpen Access

Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Meta-analysis compares overall survival and response rates in acute myeloid leukemia, highlighting differences in trial and real-world outcomes.

Overall survival was significantly longer in clinical trials at 13.98 months, compared to 9.35 months in real-world cohorts.
The combined venetoclax and hypomethylating agents produced a higher complete response rate of 67% compared to 17% with hypomethylating monotherapy.
No significant difference in composite complete response rates was found between clinical trials (52%) and real-world studies (67%).
These findings underscore the need for optimizing clinical practices to reflect better outcomes seen in trials.

Sanz-Solas et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Meta-analysis compares overall survival and response rates in acute myeloid leukemia, highlighting differences in trial and real-world outcomes.